Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

vTv Therapeutics (VTVT) Net Income (2016 - 2025)

Historic Net Income for vTv Therapeutics (VTVT) over the last 12 years, with Q3 2025 value amounting to -$10.3 million.

  • vTv Therapeutics' Net Income fell 7714.04% to -$10.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$28.4 million, marking a year-over-year decrease of 2496.81%. This contributed to the annual value of -$22.7 million for FY2024, which is 1255.87% up from last year.
  • Latest data reveals that vTv Therapeutics reported Net Income of -$10.3 million as of Q3 2025, which was down 7714.04% from -$7.4 million recorded in Q2 2025.
  • In the past 5 years, vTv Therapeutics' Net Income registered a high of -$841000.0 during Q2 2021, and its lowest value of -$10.3 million during Q3 2025.
  • In the last 5 years, vTv Therapeutics' Net Income had a median value of -$6.0 million in 2024 and averaged -$6.1 million.
  • The largest annual percentage gain for vTv Therapeutics' Net Income in the last 5 years was 8314.97% (2021), contrasted with its biggest fall of 69010.58% (2021).
  • Over the past 5 years, vTv Therapeutics' Net Income (Quarter) stood at -$9.5 million in 2021, then soared by 35.78% to -$6.1 million in 2022, then grew by 27.08% to -$4.4 million in 2023, then grew by 0.09% to -$4.4 million in 2024, then tumbled by 133.15% to -$10.3 million in 2025.
  • Its Net Income was -$10.3 million in Q3 2025, compared to -$7.4 million in Q2 2025 and -$6.2 million in Q1 2025.